CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2021; 81(05): 549-554
DOI: 10.1055/a-1390-4353
GebFra Science

Hormone Replacement Therapy After Gynaecological Malignancies: a Review Article

Article in several languages: English | deutsch
Marina Sourouni
Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Münster, Münster, Germany
Ludwig Kiesel
Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Münster, Münster, Germany
› Author Affiliations


Rapid advances in oncology have led to an increased survival rate in cancer patients, who live long enough to reach the natural age of menopause or experience the end of gonadal function as a side effect of oncological treatment. Survivors after gynaecological malignancies are a major challenge as these diseases are hormone-dependent and hormone replacement therapy (HRT) possibly increases the risk of recurrence. This article is based on a selective literature search for relevant studies and guidelines regarding HRT after gynaecological malignancies and provides a broad overview of current research. The data for assessing the oncological safety of HRT after gynaecological malignancy are insufficient overall. According to current knowledge, HRT is fundamentally contraindicated after breast and endometrial cancer. After ovarian cancer, HRT can be used after assessment of the risks and benefits, while there is usually no contraindication to HRT after vulvar, vaginal or cervical cancer.

Publication History

Received: 06 January 2021

Accepted after revision: 12 February 2021

Article published online:
20 May 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

  • References/Literatur

  • 1 Avis NE, Crawford SL, Greendale G. et al. Study of Womenʼs Health Across the Nation. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med 2015; 175: 531-539
  • 2 Gracia CR, Freeman EW. Onset of the Menopause Transition: The Earliest Signs and Symptoms. Obstet Gynecol Clin North Am 2018; 45: 585-597 DOI: 10.1016/j.ogc.2018.07.002.
  • 3 Bacon JL. The Menopausal Transition. Obstet Gynecol Clin North Am 2017; 44: 285-296 DOI: 10.1016/j.ogc.2017.02.008.
  • 4 Roberts H, Hickey M. Managing the menopause: An update. Maturitas 2016; 86: 53-58 DOI: 10.1016/j.maturitas.2016.01.007.
  • 5 Langer RD. The evidence base for HRT: what can we believe?. Climacteric 2017; 20: 91-96 DOI: 10.1080/13697137.2017.1280251.
  • 6 Antoine C, Liebens F, Carly B. et al. Safety of hormone therapy after breast cancer: a qualitative systematic review. Hum Reprod 2007; 22: 616-622
  • 7 Untch M, Beckmann MW, Emons G. et al. The LIBERATE Study: Hormone Replacement Therapy with Tibolone Increases the Risk of Recurrence and Metastases in Breast Cancer Patients. Geburtshilfe Frauenheilkd 2009; 69: 199-201
  • 8 Donders G, Neven P, Moegele M. et al. Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor((R))) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study. Breast Cancer Res Treat 2014; 145: 371-379
  • 9 Calvocoressi L, Stowe MH, Carter D. et al. Postmenopausal hormone therapy and ductal carcinoma in situ: a population-based case-control study. Cancer Epidemiol 2012; 36: 161-168
  • 10 Luo J, Cochrane BB, Wactawski-Wende J. et al. Effects of menopausal hormone therapy on ductal carcinoma in situ of the breast. Breast Cancer Res Treat 2013; 137: 915-925
  • 11 Sourouni M. Hormonersatztherapie und duktales Carcinoma in situ. J Gynäkol Endokrinol CH 2019; 22: 100-104
  • 12 Edey KA, Rundle S, Hickey M. Hormone replacement therapy for women previously treated for endometrial cancer. Cochrane Database Syst Rev 2018; (05) CD008830
  • 13 Di Donato V, Palaia I, DʼAniello D. et al. Does Hormone Replacement Therapy Impact the Prognosis in Endometrial Cancer Survivors? A Systematic Review. Oncology 2020; 98: 195-201
  • 14 Shim SH, Lee SJ, Kim SN. Effects of hormone replacement therapy on the rate of recurrence in endometrial cancer survivors: a meta-analysis. Eur J Cancer 2014; 50: 1628-1637
  • 15 Crandall CJ, Hovey KM, Andrews CA. et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Womenʼs Health Initiative Observational Study. Menopause 2018; 25: 11-20
  • 16 Deli T, Orosz M, Jakab A. Hormone Replacement Therapy in Cancer Survivors-Review of the Literature. Pathol Oncol Res 2020; 26: 63-78 DOI: 10.1007/s12253-018-00569-x.
  • 17 Li D, Ding CY, Qiu LH. Postoperative hormone replacement therapy for epithelial ovarian cancer patients: a systematic review and meta-analysis. Gynecol Oncol 2015; 139: 355-362
  • 18 Eeles RA, Morden JP, Gore M. et al. Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer: Results of the AHT Randomized Trial. J Clin Oncol 2015; 33: 4138-4144 DOI: 10.1200/JCO.2015.60.9719.
  • 19 Saeaib N, Peeyananjarassri K, Liabsuetrakul T. et al. Hormone replacement therapy after surgery for epithelial ovarian cancer. Cochrane Database Syst Rev 2020; (01) CD012559
  • 20 Mau C, Untch M. Prophylactic Surgery: For Whom, When and How?. Breast Care (Basel) 2017; 12: 379-384
  • 21 Sullivan SD, Sarrel PM, Nelson LM. Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause. Fertil Steril 2016; 106: 1588-1599
  • 22 Gordhandas S, Norquist BM, Pennington KP. et al. Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits. Gynecol Oncol 2019; 153: 192-200
  • 23 Marchetti C, De Felice F, Boccia S. et al. Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A Meta-analysis. Crit Rev Oncol Hematol 2018; 132: 111-115
  • 24 Ploch E. Hormonal replacement therapy in patients after cervical cancer treatment. Gynecol Oncol 1987; 26: 169-177
  • 25 Angioli R, Luvero D, Armento G. et al. Hormone replacement therapy in cancer survivors: Utopia?. Crit Rev Oncol Hematol 2018; 124: 51-60
  • 26 Vargiu V, Amar ID, Rosati A. et al. Hormone replacement therapy and cervical cancer: a systematic review of the literature. Climacteric 2021; 24: 120-127 DOI: 10.1080/13697137.2020.1826426.
  • 27 Rauh LA, Pannone AF, Cantrell LA. Hormone replacement therapy after treatment for cervical cancer: Are we adhering to standard of care?. Gynecol Oncol 2017; 147: 597-600
  • 28 Sherman KJ, Daling JR, McKnight B. et al. Hormonal factors in vulvar cancer. A case-control study. J Reprod Med 1994; 39: 857-861
  • 29 Herbst AL, Ulfelder H, Poskanzer DC. Adenocarcinoma of the vagina: association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med 1971; 284: 878-881
  • 30 Somoye GO, Gull S. Adenocarcinoma of the vaginal vault following prolonged unopposed oestrogen hormone replacement therapy. J Obstet Gynaecol 2005; 25: 220-221 DOI: 10.1080/01443610500050991.
  • 31 Johnson A, Roberts L, Elkins G. Complementary and Alternative Medicine for Menopause. J Evid Based Integr Med 2019; 24: 2515690X19829380